Your browser doesn't support javascript.
Mostrar: 20 | 50 | 100
Resultados 1 - 2 de 2
Mais filtros

Base de dados
Tipo de estudo
Intervalo de ano de publicação
Glob Health Action ; 12(1): 1662685, 2019.
Artigo em Inglês | MEDLINE | ID: mdl-31510887


Background: Ending AIDS as a public health threat by 2030 is a significant challenge, as new HIV infections among adolescents and young people have not decreased fast enough to curb the epidemic. The combination of slow HIV response and increasing youth populations 15-24 could affect progress towards 2030 goals. Objective: This analysis aimed to describe global and regional trends from 2010-2050 in the HIV epidemic among adolescents and young people by accounting for demographic projections and recent trends in HIV interventions. Methods: 148 national HIV estimates files were used to project the HIV epidemic to 2050. Numbers of people living with HIV and new HIV infections were projected by sex and five-year age group. Along with demographic data, projections were based on three key assumptions: future trends in HIV incidence, antiretroviral treatment coverage, and coverage of antiretrovirals for prevention of mother-to-child transmission. Results represent nine geographic regions. Results: While the number of adolescents and young people is projected to increase by 10% from 2010-2050, those living with HIV is projected to decrease by 61%. In Eastern and Southern Africa, which hosts the largest HIV epidemic, new HIV infections among adolescents and young people are projected to decline by 84% from 2010-2050. In West and Central Africa, which hosts the second-largest HIV epidemic, new infections are projected to decline by 35%. Conclusions: While adolescents and young people living with HIV are living longer and ageing into adulthood, if current trends continue, the number of new HIV infections is not projected to decline fast enough to end AIDS as a health threat in this age group. Regional variations suggest that while progress in Eastern and Southern Africa could reduce the size of the epidemic by 2050, other regions exhibit slower rates of decline among adolescents and young people.

Demografia/tendências , Infecções por HIV/epidemiologia , Adolescente , África Austral , Antirretrovirais/uso terapêutico , Bases de Dados Factuais , Feminino , Previsões , Humanos , Incidência , Transmissão Vertical de Doença Infecciosa/prevenção & controle , Masculino , Adulto Jovem
Curr HIV/AIDS Rep ; 12(2): 196-206, 2015 Jun.
Artigo em Inglês | MEDLINE | ID: mdl-25929961


Southern Africa is the region worst affected by HIV in the world and accounts for one third of the global burden of HIV. Achieving the UNAIDS 90-90-90 target by 2020 and ending the AIDS epidemic by 2030 depend on success in this region. We review epidemiological trends in each country in southern Africa with respect to the prevalence, incidence, mortality, coverage of anti-retroviral therapy (ART) and TB notification rates, to better understand progress in controlling HIV and TB and to determine what needs to be done to reach the UNAIDS targets. Significant progress has been made in controlling HIV. In all countries in the region, the prevalence of HIV in people not on ART, the incidence of HIV, AIDS-related mortality and, in most countries, TB notification rates, are falling. In some countries, the risk of infection began to fall before biomedical interventions such as ART became widely available as a result of effective prevention measures or people's awareness of, and response to, the epidemic but the reasons for these declines remain uncertain. Some countries have achieved better levels of ART coverage than others, but all are in a position to reach the 2020 and 2030 targets if they accelerate the roll-out of ART and of targeted prevention efforts. Achieving the HIV treatment targets will further reduce the incidence of HIV-related TB, but efforts to control TB in HIV-negative people must be improved and strengthened.

Erradicação de Doenças , Infecções por HIV/epidemiologia , HIV/patogenicidade , África Austral/epidemiologia , Infecções por HIV/tratamento farmacológico , Infecções por HIV/prevenção & controle , Humanos